<DOC>
	<DOCNO>NCT02212457</DOCNO>
	<brief_summary>The main purpose conduct study firstly assess immunological non-inferiority MenABCWY vaccine , administer accord 0 , 2 month schedule healthy adolescent 10 18 year age , license rMenB+OMV vaccine ( Bexseroâ„¢ ) term hSBA GMTs one month second vaccination , secondly give flexibility national vaccination program show safety immunogenicity MenABCWY administrate accord four different vaccination schedule additionally evaluate potential benefit 3-dose vaccination series .</brief_summary>
	<brief_title>Trial Assess Immunogenicity Safety Novartis Meningococcal ABCWY Vaccine Compared Meningococcal B Vaccine Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>1 . Adolecents 1018 yearsof age , generally good health , available study visit , who/whose legally acceptable representative give write informed consent time enrollment . 2 . Individuals investigator believe comply requirement protocol ( e.g . use eDiary , return followup visit , available phone contact ) . 3 . Female subject childbearing potential must negative urine preganancy test . 1 . Serious , acute , chronic illness . Previous suspected disease cause N. meningitidis . Previous immunization menincococcal Hepatitis A vaccine . 2 . Exposure individual clicically proven meningococcal disease clinical bacterial meningitis without microbiologic characteriszation .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>